This is a multicenter, open-label trial to evaluate the safety of continued therapy with
subcutaneous Remodulin® in subjects with pulmonary arterial hypertension (PAH) who complete
the CVT-CV-003 study. The study will include about 50 subjects at up to 10 clinical trial
centers in China who completed all required assessments in the CVT-CV-003 study. Study visits
for data collection will occur at month 6 and 12 with yearly visits beyond 12 months until
the study is discontinued by the sponsor.